[{"id":"5299d983-b5a6-4139-a880-c383cdcdadb8","acronym":"SPiReL","url":"https://clinicaltrials.gov/study/NCT03349450","created_at":"2021-01-18T16:32:24.143Z","updated_at":"2025-02-25T16:07:12.338Z","phase":"Phase 2","brief_title":"DPX-Survivac and Checkpoint Inhibitor in DLBCL","source_id_and_acronym":"NCT03349450 - SPiReL","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • maveropepimut-S (MVP-S) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/13/2018","start_date":" 03/13/2018","primary_txt":" Primary completion: 10/31/2021","primary_completion_date":" 10/31/2021","study_txt":" Completion: 07/18/2023","study_completion_date":" 07/18/2023","last_update_posted":"2023-11-02"},{"id":"d94de171-8220-41f2-8706-22ba38f8e320","acronym":"ETAPA I","url":"https://clinicaltrials.gov/study/NCT05283109","created_at":"2022-03-16T15:54:21.194Z","updated_at":"2024-07-02T16:35:37.647Z","phase":"Phase 1","brief_title":"ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM","source_id_and_acronym":"NCT05283109 - ETAPA I","lead_sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","biomarkers":" MGMT • BIRC5","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • P30-EPS"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/30/2023","start_date":" 08/30/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2023-09-08"},{"id":"d2d8a1f4-83ff-4a9f-8f76-430436ac978b","acronym":"ALISON","url":"https://clinicaltrials.gov/study/NCT04739527","created_at":"2021-02-04T18:58:55.737Z","updated_at":"2024-07-02T16:35:59.933Z","phase":"Phase 1","brief_title":"Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment","source_id_and_acronym":"NCT04739527 - ALISON","lead_sponsor":"University Medical Center Groningen","biomarkers":" BIRC5 • CTAG1B • PRAME","pipe":"","alterations":" ","tags":["BIRC5 • CTAG1B • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vididencel (DCP-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 06/10/2021","start_date":" 06/10/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2022-11-28"},{"id":"88aba52c-330f-4d12-911f-952efcb05266","acronym":"","url":"https://clinicaltrials.gov/study/NCT02851056","created_at":"2021-01-18T13:59:43.458Z","updated_at":"2024-07-02T16:36:00.560Z","phase":"Phase 1","brief_title":"Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)","source_id_and_acronym":"NCT02851056","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/27/2016","start_date":" 09/27/2016","primary_txt":" Primary completion: 07/16/2018","primary_completion_date":" 07/16/2018","study_txt":" Completion: 08/09/2018","study_completion_date":" 08/09/2018","last_update_posted":"2022-11-11"},{"id":"9db4be82-c625-4434-a324-3b79d8e209d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05000801","created_at":"2021-08-11T14:55:35.593Z","updated_at":"2024-07-02T16:36:26.069Z","phase":"","brief_title":"Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia","source_id_and_acronym":"NCT05000801","lead_sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","biomarkers":" WT1 • BIRC5","pipe":"","alterations":" ","tags":["WT1 • BIRC5"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2021-08-20"},{"id":"0c4d393e-bd17-43ea-b59d-e574dac72e96","acronym":"","url":"https://clinicaltrials.gov/study/NCT00118040","created_at":"2021-01-18T00:23:46.454Z","updated_at":"2024-07-02T16:36:29.291Z","phase":"Phase 2","brief_title":"Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer","source_id_and_acronym":"NCT00118040","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • BIRC5 • CASP3 • MT-CO2","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • BIRC5 • CASP3 • MT-CO2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 06/24/2005","start_date":" 06/24/2005","primary_txt":" Primary completion: 08/15/2010","primary_completion_date":" 08/15/2010","study_txt":" Completion: 08/15/2010","study_completion_date":" 08/15/2010","last_update_posted":"2021-06-10"},{"id":"bd30c023-8987-4b8d-8c2c-7885f1613d76","acronym":"","url":"https://clinicaltrials.gov/study/NCT04873180","created_at":"2021-05-05T11:52:34.984Z","updated_at":"2024-07-02T16:36:30.581Z","phase":"","brief_title":"Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma","source_id_and_acronym":"NCT04873180","lead_sponsor":"Sohag University","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression • BIRC5 overexpression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression • BIRC5 overexpression"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2021-05-07"},{"id":"f42333b8-1643-4713-b7ca-2173f42ab915","acronym":"","url":"https://clinicaltrials.gov/study/NCT02647671","created_at":"2021-01-18T12:53:02.680Z","updated_at":"2024-07-02T16:36:32.076Z","phase":"Phase 1","brief_title":"Aquamin and Prevention of Colon Cancer","source_id_and_acronym":"NCT02647671","lead_sponsor":"James Varani","biomarkers":" CDH1 • BIRC5 • CASP3","pipe":"","alterations":" ","tags":["CDH1 • BIRC5 • CASP3"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2021-04-12"},{"id":"9ba1fa58-3a34-4e19-a5e3-b32641970e8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02123381","created_at":"2021-01-18T09:50:16.450Z","updated_at":"2024-07-02T16:36:48.334Z","phase":"Phase 2","brief_title":"Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT02123381","lead_sponsor":"Sichuan Cancer Hospital and Research Institute","biomarkers":" TP53 • BIRC5","pipe":" | ","alterations":" TP53 expression • BIRC5 expression","tags":["TP53 • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression • BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2020-03-17"},{"id":"c3fca746-2c87-4c39-b71e-3fcf60265718","acronym":"PHOENIX","url":"https://clinicaltrials.gov/study/NCT03740893","created_at":"2021-01-18T18:19:29.637Z","updated_at":"2025-02-25T15:08:06.285Z","phase":"Phase 2","brief_title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer","source_id_and_acronym":"NCT03740893 - PHOENIX","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" HER-2 • ER • PGR • BRCA1 • CD8 • IFNG • LAG3 • BIRC5 • CXCL9 • PARP1 • TYMS • PTTG1 • RRM2 • CDC20 • CCNB1 • CEP55 • UBE2C","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • BRCA1 • CD8 • IFNG • LAG3 • BIRC5 • CXCL9 • PARP1 • TYMS • PTTG1 • RRM2 • CDC20 • CCNB1 • CEP55 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2020-02-21"},{"id":"4344444c-75d7-40a8-8d13-8d1190b703c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00620321","created_at":"2021-01-18T02:18:20.529Z","updated_at":"2024-07-02T16:36:55.902Z","phase":"Phase 2","brief_title":"A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT00620321","lead_sponsor":"Eli Lilly and Company","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • gataparsen (LY2181308)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 01/01/2010","primary_completion_date":" 01/01/2010","study_txt":" Completion: 01/01/2010","study_completion_date":" 01/01/2010","last_update_posted":"2019-09-09"},{"id":"d5c302f6-f239-4bba-903a-aaad67b7c5f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00129376","created_at":"2021-01-18T00:26:20.714Z","updated_at":"2024-07-02T16:36:58.407Z","phase":"Phase 2","brief_title":"Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients","source_id_and_acronym":"NCT00129376","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression • BIRC5 overexpression • CDKN1B expression • TOP2A expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression • BIRC5 overexpression • CDKN1B expression • TOP2A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 02/01/2003","start_date":" 02/01/2003","primary_txt":" Primary completion: 07/01/2005","primary_completion_date":" 07/01/2005","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2019-07-05"},{"id":"7fc944c0-52e2-402d-9521-56f61f9ca32e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00320411","created_at":"2021-01-18T01:06:12.786Z","updated_at":"2024-07-02T16:37:03.302Z","phase":"Phase 2","brief_title":"GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer","source_id_and_acronym":"NCT00320411","lead_sponsor":"GlaxoSmithKline","biomarkers":" EGFR • HER-2 • BCL2 • ERBB3 • ERBB4 • BIRC5","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["EGFR • HER-2 • BCL2 • ERBB3 • ERBB4 • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 11/28/2005","start_date":" 11/28/2005","primary_txt":" Primary completion: 04/01/2009","primary_completion_date":" 04/01/2009","study_txt":" Completion: 04/01/2009","study_completion_date":" 04/01/2009","last_update_posted":"2019-01-31"},{"id":"df9ef5ca-d318-4e93-9501-779e49ce9ce1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01764477","created_at":"2021-01-18T07:45:28.718Z","updated_at":"2024-07-02T16:37:18.793Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT01764477","lead_sponsor":"Prism Pharma Co., Ltd.","biomarkers":" BIRC5 • MMP7","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5 • MMP7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • foscenvivint (PRI724)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2017-08-17"},{"id":"b35e4385-5542-41cd-ab43-a9571f86de15","acronym":"","url":"https://clinicaltrials.gov/study/NCT01416038","created_at":"2021-01-18T05:49:49.052Z","updated_at":"2024-07-02T16:37:23.200Z","phase":"Phase 1","brief_title":"Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer","source_id_and_acronym":"NCT01416038","lead_sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","biomarkers":" BIRC5","pipe":"","alterations":" ","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • maveropepimut-S (MVP-S) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2017-04-21"},{"id":"5a7c5489-b239-47d8-a356-42d94714ee1a","acronym":"PRIMIER","url":"https://clinicaltrials.gov/study/NCT02413853","created_at":"2021-01-18T11:31:51.660Z","updated_at":"2024-07-02T16:37:23.393Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02413853 - PRIMIER","lead_sponsor":"University of Southern California","biomarkers":" BRAF • BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BRAF • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • foscenvivint (PRI724)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2017-04-17"},{"id":"3ca821ef-423b-485d-8f1b-2540048b714e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00365872","created_at":"2021-01-18T01:16:14.780Z","updated_at":"2024-07-02T16:37:24.158Z","phase":"Phase 2","brief_title":"External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma","source_id_and_acronym":"NCT00365872","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IFNG • BIRC5","pipe":"","alterations":" ","tags":["IFNG • BIRC5"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2017-03-23"},{"id":"6023bb5b-95ce-4a1c-8bf6-99e41dfe3530","acronym":"POLYTCANCER","url":"https://clinicaltrials.gov/study/NCT02880046","created_at":"2021-01-18T14:08:20.300Z","updated_at":"2024-07-02T16:37:29.534Z","phase":"","brief_title":"Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies","source_id_and_acronym":"NCT02880046 - POLYTCANCER","lead_sponsor":"Central Hospital, Nancy, France","biomarkers":" IFNG • BIRC5","pipe":"","alterations":" ","tags":["IFNG • BIRC5"],"overall_status":"Unknown status","enrollment":" Enrollment 90","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 10/01/2017","study_completion_date":" 10/01/2017","last_update_posted":"2016-08-26"}]